Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AKRO 
Akero Therapeutics Inc (AKRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: AKRO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $77.3
1 Year Target Price $77.3
| 9 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.39% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.48B USD | Price to earnings Ratio - | 1Y Target Price 77.3 |
Price to earnings Ratio - | 1Y Target Price 77.3 | ||
Volume (30-day avg) 12 | Beta -0.24 | 52 Weeks Range 21.34 - 58.40 | Updated Date 09/13/2025 |
52 Weeks Range 21.34 - 58.40 | Updated Date 09/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.81 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -20.36% | Return on Equity (TTM) -31.14% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2771194853 | Price to Sales(TTM) - |
Enterprise Value 2771194853 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.77 | Shares Outstanding 79989000 | Shares Floating 67769859 |
Shares Outstanding 79989000 | Shares Floating 67769859 | ||
Percent Insiders 1.14 | Percent Institutions 116.23 |
Upturn AI SWOT
Akero Therapeutics Inc
Company Overview
History and Background
Akero Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2017. It focuses on developing treatments for non-alcoholic steatohepatitis (NASH) and other metabolic diseases. The company is based in South San Francisco, California.
Core Business Areas
- NASH Therapeutics Development: Akero's primary focus is developing and commercializing therapies for NASH, a liver disease characterized by inflammation and fat accumulation.
Leadership and Structure
Andrew Cheng, M.D., Ph.D. is the President and CEO. The company has a board of directors and a management team overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- Efcarmotegravir: Efcarmotegravir is Akero's lead product candidate, a fibroblast growth factor 21 (FGF21) analog being developed for the treatment of NASH. It's currently in Phase 2b/3 clinical trials. Market share is currently 0 as the product is still in development. Competitors include Madrigal Pharmaceuticals (resmetirom) and Viking Therapeutics (VK2809).
Market Dynamics
Industry Overview
The NASH therapeutics market is a rapidly growing area, driven by the increasing prevalence of obesity and related metabolic disorders. Several companies are developing novel therapies to address this unmet medical need.
Positioning
Akero is positioning itself as a leader in the NASH space with Efcarmotegravir, aiming to provide a differentiated treatment option with improved efficacy and safety profile compared to existing or near-term competitors.
Total Addressable Market (TAM)
The NASH market is projected to reach tens of billions of dollars annually. Akero aims to capture a significant portion of this market with Efcarmotegravir, especially if it demonstrates superior efficacy and safety in clinical trials.
Upturn SWOT Analysis
Strengths
- Novel FGF21 analog mechanism of action
- Promising Phase 2b clinical trial data
- Experienced management team
- Strong intellectual property position
Weaknesses
- Clinical development risk (drug may not be approved)
- Reliance on a single lead product candidate
- High cash burn rate associated with clinical trials
- Competition from larger pharmaceutical companies
Opportunities
- Positive Phase 3 clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other metabolic disease indications
- Accelerated regulatory approval pathways
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from other NASH therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- MDGL
- VKTX
- GILD
Competitive Landscape
Akero operates in a competitive landscape with companies like Madrigal (MDGL) and Viking (VKTX) developing their own NASH therapies. Madrigal has already obtained FDA approval for its drug Resmetirom. Akero's success depends on demonstrating superior efficacy or a differentiated safety profile.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been defined by advancement of its lead drug candidate through clinical trials, not revenue. The company's value is based on investor anticipation of successful clinical trial outcomes and regulatory approval.
Future Projections: Future growth is dependent on the successful completion of Phase 3 trials and regulatory approval of Efcarmotegravir. Analyst estimates are optimistic but highly variable, contingent on positive data releases.
Recent Initiatives: Recent initiatives include enrolling patients in Phase 3 trials and exploring potential partnerships to support commercialization efforts.
Summary
Akero Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for NASH. Its lead candidate, Efcarmotegravir, is in Phase 3 trials and represents a potential growth driver. The company faces clinical trial risks and intense competition. Successful Phase 3 results are critical for its long-term success and shareholder value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own research and due diligence. Market share percentages are estimates and can vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akero Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-06-20 | President, CEO & Director Dr. Andrew Cheng M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 67 | Website https://akerotx.com |
Full time employees 67 | Website https://akerotx.com | ||
Akero Therapeutics, Inc. engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.